Okay, I will analyze the provided text regarding FDA approvals of GLP-1s and verify the claims made within, using web searches to ensure accuracy and provide updates as needed. I will then present a summary of FDA approvals,incorporating the information from the text and my findings.
Analysis of Provided Text & Verification
The text focuses on a KFF analysis of GLP-1 prescription and spending data within Medicaid from 2019-2024, using State Drug Utilization Data (SDUD). It details the methodology for identifying GLP-1s (using ATC codes) and lists the drugs included in the analysis. It also outlines limitations of the data.
Here’s a breakdown of verification points and updates:
* State Drug Utilization Data (SDUD): The link provided (https://www.medicaid.gov/medicaid/prescription-drugs/state-drug-utilization-data/index.html) is correct and leads to the official CMS SDUD page. The description of the data is accurate.
* ATC Classification: The link to the WHO’s ATC system (https://www.who.int/tools/atc-ddd-toolkit/atc-classification) is also correct.
* GLP-1 & Tirzepatide Identification: The use of ATC codes “A10BJ” for GLP-1 analogues and “A10BX” for tirzepatide (and other blood glucose lowering drugs) is a valid method for identifying these drugs in the SDUD.
* Drug List: The list of drugs included (Ozempic, Rybelsus, Mounjaro, Victoza, Trulicity, Wegovy, Zepbound, Saxenda, generic liraglutide, Adlyxin, Byetta, Bydureon BCise, and Tanzeum) is generally accurate as of late 2023/early 2024. However, Tanzeum is discontinued as noted in the text.
* Data Download Date: The text states the data was downloaded in January 2026. This is an error. It should be January 2024 or 2025, as we are currently in 2024. This is a critical error to correct.
* Limitations: The listed limitations are valid and important to consider when interpreting the data. The SDUD data does not include days supplied, rebates are not factored in, and data is subject to revision with quarterly updates.
FDA Approvals of GLP-1s (Updated as of February 29, 2024)
Here’s a thorough list of FDA-approved GLP-1 receptor agonists, categorized by their primary indication (Type 2 Diabetes or Obesity), and including approval dates. This incorporates the information from the provided text and my web search results.
I. For Type 2 Diabetes
* Exenatide (Byetta): April 2005 (first GLP-1 approved)
* Liraglutide (Victoza): January 2010
* Exenatide Extended-Release (Bydureon BCise): February 2012
* Lixisenatide (Adlyxin): January 2016
* Dulaglutide (Trulicity): September 2014
* Semaglutide (ozempic): December 2017
* Liraglutide (Rybelsus): September 2019 (oral formulation)
II. For Obesity (and continued use for Type 2 Diabetes)
* Liraglutide (Saxenda): december 2014 (higher dose of Victoza)
* Semaglutide (Wegovy): June 2021 (higher dose of Ozempic)
* Tirzepatide (Zepbound): May 2023